Advice
following an abbreviated submission:
rilpivirine (Edurant®) is accepted for use within NHS Scotland.
Indication under review: in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients aged 12 to 18 years of age and older with a viral load (VL) ≤ 100,000 HIV-1 RNA copies/mL.
The Scottish Medicines Consortium has previously accepted rilpivirine in this indication in adult patients.
Download detailed advice116KB (PDF)
Medicine details
- Medicine name:
- rilpivirine hydrochloride (Edurant)
- SMC ID:
- 1168/16
- Indication:
- In combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients aged 12 to 18 years of age and older with a viral load (VL) ≤100,000 HIV-1 RNA copies/mL.
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 08 August 2016